Read more
3:48 PM · 19 December 2023

CureVac loses 34% as German court quashes company's patent

-
-
Open account Download free app

CureVac (CVAC.US) loses more than 30% today after a German court quashed a company's patent. As Reuters analysis reports, the patent in question is one of several intellectual property titles that CureVac claims were infringed in ongoing legal proceedings. The patent was also the basis of a patent violation lawsuit by CureVac against its market rival and mRNA vaccines producer, BioNTech (BNTX.US), in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. As presiding judge in Germany's patent court, said in his ruling after a hearing, the patent is now invalid for the Germany territory. Biontech's shares are up 2% today. CureVac'smRNA-based COVID-19 vaccine didn't bring any significant cash from sales. At the same time, BioNTech / Pfizer collaboration made more than $40 billion in combined vaccines sales in 2021 and 2022. 

Source: xStation5

30 March 2026, 5:02 PM

Microsoft and the Next Phase of AI: Market Focus on Adoption and Profits

30 March 2026, 3:01 PM

US Open: A Tentative Start to the New Week on Wall Street!

27 March 2026, 6:24 PM

Anthropic leak and a cybersecurity sell-off

27 March 2026, 5:22 PM

Unity up 10% 🚨 A revolution at the company?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits